Fresh Start For Insmed, Added Biosimilar Capabilities For Merck In $130M Deal

By purchasing Insmed’s follow-on biologics pipeline and facility, Merck BioVentures is poised for bigger attack on Amgen blockbusters.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet